Assessment of Time-to-onset and Outcome of Lung Adverse Events With Pomalidomide from a Pharmacovigilance Study
Sign Up to like & getrecommendations! Published in 2023 at "In Vivo"
DOI: 10.21873/invivo.13168
Abstract: Abstract Background/Aim: Pomalidomide is an immunomodulatory drug that is used to treat multiple myeloma. We examined the time-to-onset and outcome of lung adverse events (LAEs) related to pomalidomide in Japanese patients based on information obtained… read more here.
Keywords: time; onset outcome; pneumonia; outcome lung ... See more keywords
Evaluation of the Time to Onset and Outcome of Lenalidomide-induced Thrombosis and Embolism Using Spontaneous Reporting Database
Sign Up to like & getrecommendations! Published in 2023 at "In Vivo"
DOI: 10.21873/invivo.13201
Abstract: Background/Aim: Lenalidomide (LND) is an oral antineoplastic agent used in the treatment of various malignant hematologic diseases, including multiple myeloma. Major adverse events of LND include myelosuppression, pneumonia, and thromboembolism. Thromboembolism is an adverse drug… read more here.
Keywords: onset outcome; database; time onset; thrombosis ... See more keywords